Brief: Rigel Pharmaceuticals Q2 EPS USD -0.06 Vs. IBES Estimate USD -0.29
06/08/2024 21:01
Aug 06 (Reuters) - Rigel Pharmaceuticals Q2 revenue USD 36.8 million vs. IBES estimate USD 33.4 million. * Q2 net income USD -1 million vs. IBES estimate USD -5.43 million
Recent news on Rigel Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue rises on strong product demand
Brief: Rigel Pharmaceuticals - Appoints Alison L. Hannah As Executive Vice President And Chief Medical Officer Effective July 1, 2026 - SEC Filing
Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)